Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 6
Submit an article Journal homepage
89
Views
2
CrossRef citations to date
0
Altmetric
Review

The safety and efficacy of the use of vasopressin in sepsis and septic shock

Stephen J Wilson St James’s University Hospital, Intensive Care Unit, Leeds, LS9 7TF, UK. [email protected]
,
Saurabh S Mehta St James’s University Hospital, Intensive Care Unit, Leeds, LS9 7TF, UK. [email protected]
&
Mark C Bellamy St James’s University Hospital, Intensive Care Unit, Leeds, LS9 7TF, UK. [email protected]
Pages 1027-1039 | Published online: 28 Oct 2005

Bibliography

  • AMERICAN COLLEGE OF CHEST PHYSICIANS/SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Grit. Care Med. (1992) 20:864–874.
  • DELLINGER R, CARLET J, MASUR H et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Grit. Care Med. (2004) 32:858–871.
  • ••Well researched expert opinion.
  • MEIER-HELLMAN A, VLASAKOV K: Management of sepsis. European Socieo, of Anaesthesiology, Euroanaesthesia 2004, Lisbon, Portugal (2004) 12RC2.
  • HOTCHKISS R, KARL I: The pathophysiology and treatment of sepsis. N Eng]. J. Med. (2003) 348:138–150.
  • OLIVER G, SCHAEFER AE: On the physiological action of extract of pituitary body and certain other glandular organs. J. Physic] (1895) 18:277–279.
  • HADENGUE A, GADANO A, MOREAU R et al: Beneficial effects of the 2-day administration of Terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol (1998) 29:565–570.
  • RESTUCCIA T, ORTEGA R, GUEVARA M et al: Effects of treatment of hepatorenal syndrome before transplantation on post-transplantation outcome. A case control study. J. Hepatol (2004) 40:140–146.
  • IANNOU G, DOUST J, ROCKEY D: Systematic review: Terlipressin for acute oesophageal variceal haemorrhage. Aliment. Pharmacol. Ther. (2003) 17:53–64.
  • MOREAU R, ASSELAH T, CONDAT B et al: Comparison of the effect of Terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites being treated by paracentesis: a randomised pilot study. Gut (2002) 50:90–94.
  • WENZEL V, KRISMER AC, ARNTZ HR et al.: A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N. Eng]. J. Med. (2004) 350:105–113.
  • HOGG K, MAHU R: Vasopressin or adrenaline in cardiac resuscitation. Emig. Med. J. (2003) 20:467.
  • AUNG K, HTAY T: Vasopressin for Cardiac Arrest: A Systematic Review and Meta-analysis. Arch. Intern. Med. (2005) 165:17–24.
  • MORELLI A„ et al: Terlipressin versusnorepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology (2005) 102:12–9.
  • DUNN FL, BRENNAN TJ, NELSON AE, ROBERTSON GL: The role of blood osmolality and volume in regulating vasopressin secretion in the rat. Clin. Invest. (1973) 52:3212–3219.
  • WADE CE, KEIL LC, RAMSAY DJ: Role of volume and osmolality in the control of plasma vasopressin in dehydrated dogs. Neuroendocrinology (1983) 37:349–343.
  • COWLEY AW Jr, CUSHMAN WC, QUILLEN EW Jr, SKELTON MM, LANGFORD HG: Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension (1981) 3:193–1100.
  • BERL T, ROBERTSON GL: Pathophysiology of water metabolism. In: Brenner and Rector's The Kidney. Brenner BM (Ed), Saunders, Philadelphia (2000):866–924.
  • ROBINSON AG, VERBALIS JG: Posterior pituitary gland. In: Williams Textbook of Endocrinology. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (Eds), Saunders, Philadelphia (2003):281–330.
  • ROBERTSON GL, SHELTON RL, ATHAR S: The osmoregulation of vasopressin. Kidney Int. (1976) 10:25–37.
  • BIRNBAUMER M: Vasopressin receptors. Trends Endocrinol Metab. (2000) 11:406–410.
  • MANNUCCI PM, ABERG M, NILSSON IM, ROBERTSON B: Mechanism of plasminogen activator and Factor VIII increase after vasoactive drugs. Br. J. Haematol (1975) 30:81–93.
  • RICHARDSON DW, ROBINSON AG: Desmopressin. Ann. Intern. Med. (1985) 103:228–239.
  • SUGIMOTO T, SAITO M, MOCHIZUKI S, WATANABE Y, HASHIMOTO S, KAWASHIMA H: Molecular cloning and functional expression of a cDNA encoding the human Vlb vasopressin receptor. J. Biol. Chem. (1994) 269.27088–27092.
  • THIBONNIER M, PRESTON J, DULIN N, WILKINS P, BERTI-MATTERA L, MATTERA R: The human V3 pituitary vasopressin receptor. Ligand binding profile and density-dependent signalling pathways. Endocrinology (1997) 138:4109–4122.
  • THIBONNIER M, CON ORTY D, PRESTON J, PLEISNICHER C, DWEIK R, ERZURUM S: Human vascular endothelial cells express oxytocin receptors. Endocrinology (1999) 140:1301–1309.
  • WILSON M, BRACKETT D, TOMPKINS P, BENJAMIN B, ARCHER L, HINSHAW L: Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv. Shock Res. (1981) 6:15–26.
  • BRACKETT D, SCHAEFER C TOMPKINS P, FAGRAEUS L, PETERS L, WILSON M: Evaluation of cardiac output, total peripheral resistance and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ. Shock (1985) 17:273–284.
  • KASTING N, MAZUREK M, MARTIN J:Endotoxin increases vasopressin release independently of known physiological stimuli. Am. J. Phyisol (1985) 248:E420–E424.
  • MASTORAKOS G, WEBER J, MAGIAKOU M, GUNN H, CHROUSOS G: Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. Endocrinol Metab. (1994) 79:934–939.
  • CHIKANZA I, PETROU P, CHROUSOS G: Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann. NY Acad. Sci. (2000) 917:825–834.
  • ZELAZOWSKI P, PATCHEV V, ZELAZOWSKA E, CHROUSOS G, GOLD P, STERNBERG E: Release of hypothalamic corticotrophin releasing hormone and arginine-vasopressin by interleukin 1 beta and alpha MSH: studies in rats with different susceptibilities to inflammatory disease. Brain Res. (1993) 631:22–26.
  • SHARSHAR T, BLANCHFORD A, PAILLARD M, RAPHAEL J, GAJDOS P, ANNANE D: Circulating vasopressin levels in septic shock. Crit. Care Med. (2003) 31:1752–1758.
  • LANDRY D, LEVIN H, GALLANT E et al.: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation (1997) 95:1122–1125.
  • •Good physiological explanation for the hypotension in sepsis.
  • BUCHER M, HOBBHAHN J, TAEGER K, KURTZ A: Cytokine mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am. I Physiol Regul Integr Comp Physiol (2002) 282:R979–R984.
  • KUSANO E, TIAN S, UMINO T et al.:Arginine vasopressin inhibits interleukin 1 beta stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. ./. Hypertens. (1997) 15:627–632.
  • WAKATSUKI T, NAKAYA Y, INOUE I: Vasopressin modulates K+-channel activities of cultured smooth muscle cells from porcine coronary artery. Am. J. Physiol (1992) 263:H491–H496.
  • MOLLNER M, URBANEK B, HAVEL C, LOSERT H, WAECHTER F, GAMPER G: Vasopressors for shock. Cochrane Database Syst. Rev (2004) Issue 3. CD003709.pub2.
  • ••The only systematic review on this topic.
  • BEALE R, HOLLENBERG S, VINCENT J, PARILLO J: Vasopressor and inotropic support in septic shock: an evidence based review. Crit. Care Med. (2004) 32:S455–S465.
  • CHEN J, CULLINANE S, SPANIER Tet al.: Vasopressor deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation (1999) 100:11244–11246.
  • BOCCARA G, OUATTARA A, GODET G et al.: Terlipressin versus Norepinephrine to correct refractory arterial hypotension after general anaesthesia in patients chronically treated with rennin angiotensin system inhibitors. Anesthesiology (2003) 98:1338–1344.
  • EYRAUD D, BRABANT S, NATHALIE D et al: The treatment of intraoperative refractory hypotension with Terlipressin in patients chronically treated with an antagonist of the renin angiotensin system. Arresth. Analg. (1999) 88:980–984.
  • ARGENZIANO M, CHOUDHRI A, OZ M, ROSE E, SMITH C, LANDRY D: A prospective randomised trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation (1997) 96:11286–11290.
  • •Well constructed RCT.
  • ARGENZIANO M, CHEN J, CHOUDHRI A et al.: Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac. Cardiovasc. &mg. (1998) 116:973–980.
  • GOLD J, CULLINANE S, CHEN J et al:Vasopressin in the treatment of milrinone induced hypotension in severe heart failure. Am. J. Cardia (2000) 85:506-588, All.
  • ROSENZWEIG E, STARC T, CHEN J et al.: Intravenous arginine vasopressin in children with vasodilatory shock after cardiac surgery. Circulation (1999) 100:11182–11186.
  • MALAY M, ASHTON R, LANDRY D et al: Low dose vasopressin in the treatment of vasodilatory septic shock. J. Trauma (1999) 47:699–703.
  • •Interesting addition to the evidence base.
  • TSUNEYOSHI I, YAMADA H, KAKIHANA Y et al.: Hemodynamic and metabolic effects of low dose vasopressin infusions in vasodilatory septic shock. Grit. Care Med. (2001) 29:487–493.
  • •Interesting addition to the evidence base.
  • PATEL B, CHITTOCK D, RUSSELL J, WALLEY K: Beneficial effects of short term vasopressin infusion during severe septic shock. Anesthesia (2002) 96:576–582.
  • •Interesting addition to the evidence base.
  • VINCENT J, DE MENDONCA A, CANTRAINE F et al.: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentre, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Grit. Care Med. (1998) 26:1793–1800.
  • MUTLU G, FACTOR P: Role of vasopressin in the management of septic shock. Intensive Care Med. (2004) 30:1276–1291.
  • •Good review of vasopressin In septic shock management.
  • VAN HAREN F, ROZENDAAL F, VAN DER HOEVEN J: The effect of vasopressin on gastric perfusion in catecholamine dependent patients in septic shock. Chest (2003) 124:2256–2260.
  • HAMU Y, KANMURA Y, TSUNEYOSHI I et al: The effects of vasopressin on endotoxin-induced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth. Analg. (1999) 88:542–548.
  • VARGA C, PAVO I, LAMARQUE D et al: Endogenous vasopressin increases acute endotoxin shock-provoked gastrointestinal mucosal injury in the rat. Eur. j Pharmacol (1998) 352:257–261.
  • DUNSER M, MAYR A, ULMER H et al.: Arginine vasopressin in advanced vasodilatory shock. A prospective, randomised, controlled study. Circulation (2003) 107:2313–2319.
  • ••Well constructed RCT.
  • LANDRY D, LEVIN H, GALLANT E: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Grit. Care Med. (1997) 25:1279–1282.
  • O'BRIEN A, CLAPP L, SINGER M: Terlipressin for Norepinephrine resistant septic shock. Lancet (2002) 359:1209–1210.
  • OBRITSCH M, JUNG R, FISH D, MACLAREN R: Effects of low dose vasopressin infusion in patients with septic shock. Ann. Pharmacother. (2004) 38:1117–1122.
  • HOLMES C, WALLEY K, CHITTOCK D, LEHMAN T, RUSSELL J: The effects of vasopressin on haemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. (2001) 27:1416–1421.
  • MORELLI A, ROCCO M, CONTI G et al: Effects of Terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med. (2004) 30:597–604.
  • DUNSER M, MAYR A, TUR A et al: Ischaemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Grit. Care Med. (2003) 31:1394–1398.
  • MOLOS M, HALL J: Symmetrical peripheral gangrene and disseminated intravascular coagulation. Arch. Dermata (1985) 121:1057–1061.
  • RODRIGUEZ-NUNEZ A, FERNANDEZ-SANMARTIN M, MARTINON-TOREZ F, GONZALES-ALONSO N, MARTINON-SANCHEZ J: Terlipressin for catecholamine resistant septic shock in children. Intensive Care Med. (2004) 30:477–480.
  • KHAN J, KRESS J, HALL J: Skin necrosisafter extravasation of low dose vasopressin administered for septic shock. Grit. Care Med. (2002) 30:1899–1901.
  • GARCIA A, SANDOVAL J, AGUIRRE J, ELIZALDE J, FRANCO J, MARTINEZ J: Vasopressin infusion improves the hemodynamics in patients with septic shock (Abstract). Grit. Care Med. (2001) 29:A90.
  • DABBAGH 0, AYOUB H, ALSHIRWAI N, ARABI Y, AL SHIMEMERI A: Use of vasopressin infusion as salvage therapy in septic patients on high dose catecholamines (Abstract). Chest (2003) 124:S224.
  • BRACCO D, CHIOLERO R, REVELLY J: Systemic and splanchnic haemodynamic effects of vasopressin administration in vasodilatory shock (Abstract). Intensive Care Med. (2001) 27:S138.
  • MANN H, BEILMAN G, BOM SONG J, HASINOFF I, LOHR B: Outcome of vasopressin treatment in vasodilatory septic shock (Abstract). Grit. Care Med. (2000) 28:A184.
  • GARCIA R, FRANCO J, AGUIRRE J, MARTINEZ J: Haemodynamic effects of early vasopressin infusion during septic shock (Abstract). Grit. Care Med. (2002) 30:A107.
  • ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY: Pitressin. In: ABPI Compendium of data sheets and summaries of product characteristics. Walker G (Ed.), Datapharm Publications Ltd, London (1998-1999) p946.
  • ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY: Glypressin. In: ABPI Compendium of data sheets and summaries of product characteristics. Walker G (Ed.), Datapharm Publications Ltd, London (1998–1999):391.
  • British National Formulary. Mehta K (Ed.), British Medical Association and Royal Pharmaceutical Society of Great Britain, London (March 2005):379–381.
  • RIVERS E, NGUYEN B, HAVSTAD S et al.: Early goal directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. (2001) 345:1368–1377.
  • ••A seminal article in intensive caretreatment.
  • KLINZING S, SIMON M, REINHART K, BREDLE DL, MEIER-HELLMANN A: High-dose vasopressin is not superior to norepinephrine in septic shock. Grit. Care Med. (2003) 31:2646–2650.

Websites

  • www.abstracts-on-line.comiabstracts/ATS/ windowview.asp?abs=ATS2L_202069 MALEVANOV M, KLAPHOLZ A, DINAN W, TALAVERA W: Vasopressin therapy in patients with refractory shock (Abstract). (Unavailable for review May 2005).
  • www.abstracts-on-line.com/abstracts/ATS/ windowview.asp?abs=ATS2L_201063 ANWAR M, ADAMS R: Effect of vasopressin on hemodynamic profile in patients with septic shock (Abstract). (Unavailable for review May 2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.